|Public limited company|
May 16, 2013Actavis) & Warner Chilcott upon the combination of Allergan Finance, LLC (|
March 17, 2015 renamed to Allergan Plc upon the merger of Allergan, Inc and Actavis
Number of locations
|40 manufacturing facilities, 27 global R&D centres and marketing/sales facilities worldwide.|
|Revenue||$15.940 billion (2017)|
|-$5.921 billion (2017)|
|-$4.403 billion (2017)|
|Total assets||$118.351 billion (2017)|
|Total equity||$73.837 billion (2017)|
Number of employees
Footnotes / references|
Allergan plc is a multinational company in the pharmaceutical industry that produces branded drugs and performs pharmaceutical research and development. It was formed on February 18, 2015, when its predecessor, Actavis, acquired the pre-2015 Allergan, Inc. and assumed the Allergan name.
The company markets brand products in six therapeutic areas: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease. The company's products include Botox (Botulinum toxin), Namenda (Memantine), Restasis (Ciclosporin), Linzess (Linaclotide), Bystolic (Nebivolol), Juvederm (Injectable filler), Latisse (Bimatoprost), Lo Loestrin Fe, Estrace (Estradiol), Teflaro, Dalvance (Dalbavancin, Ozurdex (Dexamethasone), Optive, Natrelle, Viibryd (Vilazodone), Liletta (Levonorgestrel), Saphris (Asenapine), Enablex (Darifenacin), Actonel (Risedronic acid), Androderm (Testosterone), and Gelnique (Oxybutynin).
- 1 History
- 1.1 Predecessor companies
- 1.2 Recent developments
- 1.3 Acquisition history
- 2 See also
- 3 References
- 4 External links
In the spring of 1983, colleagues Allen Chao and David Hsia formed Watson Pharmaceuticals, a small drug development company with funding from friends and family. The founders established an initial product development and analytical laboratory with four other employees in a leased space in Libertyville, Illinois.
In late fall of 1983, the company moved to a 2,000-square-foot leased facility in Corona, California and began the development and manufacturing of generic pharmaceuticals.
In 1950, pharmacist Gavin S. Herbert established Allergan Pharmaceuticals, Inc. Allergan focused on the discovery and development of novel formulations for specialty markets, as well as intimate collaboration with physicians and the scientific community. In 1953, Allergan produced eye drops and formulated new products such as the first cortisone eye drop to treat allergic inflammation and the first ophthalmic steroid decongestant.
In 1970, the company became a public company via an initial public offering. In 1980, it was acquired by SmithKline Beckman for $259 million in 1980. In 1989, Allergan was spun-off by SmithKline Beckman.
In 1998, David E.I. Pyott became chief executive officer of the company, a position he held until the merger in 2015.
On March 1, 2013, the company acquired MAP Pharmaceuticals for approximately $958 million. In December, the company sold its obesity intervention business to Apollo Endosurgery, for a cash payment of $75 million and $15 million of stock.
Merger of Actavis and Allergan
2015: Abandoned merger with Pfizer
On July 7, 2015, the company acquired the rights to the late stage CGRP migraine portfolio of Merck & Co, as well as two experimental drugs (MK-1602 and MK-8031) for an upfront payment of $250 million. On August 10, the company acquired Oculeve for $125 million. On August 31, the company acquired Naurex for an upfront payment of $560 million. On October 19, the company acquired AqueSys, developer of ocular implants that reduce intraocular pressure associated with glaucoma, for an initial payment of $300 million. On October 1, the company acquired Kythera Biopharmaceuticals, a company focused on the medical aesthetics market, for $2.1 billion. On November 4 the company announced the acquisition of Northwood Medical Innovation, developer of earFold, a medical device to correct protruding ears. On November 25, 2015, the company announced it would partner with Rugen Therapeutic to develop new therapies for autism spectrum disorder, rabies and obsessive compulsive disorder.
On November 23, 2015, Allergan and Pfizer announced their intention to merge in a $160 billion transaction, the largest pharmaceutical deal and the third largest merger in history. On April 5, 2016, after the Obama administration announced its plan to ban tax inversions, Pfizer terminated the acquisition and paid Allergan a $150 million breakup fee.
2016: Sale of Actavis Generics to Teva
On April 6, 2016, the company announced it would partner with Heptares Therapeutics in a deal valued up to $3.3 billion to collaborate on the development of a subtype-selective muscarinic agonists for Alzheimer's disease and other major neurological disorders. On April 21, the company announced the acquisition of Topokine Therapeutics for at least $85 million, gaining the phase IIb/III compound XAF5 - a treatment for dermatochalasis. On August 2, the company sold its generic drugs business to Teva Pharmaceutical Industries for $33.4 billion and 100.3 million shares of Teva. On August 11, the company announced the acquisition of ForSight VISION5 for more than $95 million. On September 6, the company acquired RetroSense Therapeutics for more than $60 million, gaining the positive photosensitivity gene therapy treatment, RST-001. RST-001 is to be used in retinas in which rod and cone photoreceptors have degenerated over time, causing in increase in the sensitivity of light hitting the retina. On September 20, the company announced the acquisition of Tobira Therapeutics for $1.695 billion and, a day later, the acquisition of Akarna Therapeutics for $50 million. On October 3, the company sold Anda, its generic drug distribution business, to Teva for $500 million. On October 25, the company acquired Vitae Pharmaceuticals, focused on dermatology treatments, for $639 million. On October 27, the company announced it would acquire Motus Therapeutics, a developer of treatments for gastrointestinal disorders, for $200 million. On November 22, 2016, the company acquired Chase Pharmaceuticals for an upfront payment of $125 million.
2017: Continuation of bolt-on acquisitions
On February 1, 2017, the company acquired LifeCell, a specialist in regenerative medicine, for $2.9 billion. On April 28, the company acquired Zeltiq Aesthetics, marketer of a cryolipolysis procedure, for $2.4 billion. On June 7, the company announced the acquisition of Keller Medical, a company that manufactures devices for use during breast augmentation surgery. On December 12, the company announced the acquisition of Repros Therapeutics, a developer of drugs for reproductive system diseases.
2018: Opioid epidemic
In 2018, along with several other drug manufacturers and distributors, the company was sued by several municipalities and states in the U.S. due to the manufacture by the company of opioids, which have been abused in what is known as the opioid epidemic.
- Biotech and pharmaceutical companies in the New York metropolitan area
- The St. Regis Mohawk Tribe and Restasis patent
- Corporation tax in the Republic of Ireland#Corporate tax inversions
- "Allergan plc 2017 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
- Todd, Susan (January 30, 2012). "Generic drug maker Watson opening research operations in North Brunswick". NJ.com.
- "Watson Completes Actavis Acquisition" (Press release). PR Newswire. October 31, 2012.
- "Actavis Completes Warner Chilcott Acquisition" (Press release). PR Newswire. October 1, 2013.
- Berkman, Leslie (July 27, 1989). "Shareholders OK SmithKline Deal Spinning Off Beckman, Allergan". Los Angeles Times.
- "Eye-Care Firm Spins Off From Allergan". Los Angeles Times. Associated Press. July 2, 2002.
- Piccalo, Gina (September 22, 2003). "Taking aim at Botox". Los Angeles Times. ISSN 0458-3035.
- "MAP Pharmaceuticals Inc. Form 8-K". U.S. Securities and Exchange Commission. March 1, 2013.
- "Allergan, Inc. Completes Sale of Obesity Intervention Business" (Press release). Business Wire. December 2, 2013.
- "Actavis Completes Allergan Acquisition" (Press release). PR Newswire. March 17, 2015.
- "Actavis plc is now Allergan plc" (Press release). PR Newswire. June 15, 2015.
- Dulaney, Chelsey (July 7, 2015). "Allergan Buys Rights to Merck's Migraine Drugs". The Wall Street Journal.
- "Allergan Successfully Completes Oculeve Acquisition" (Press release). PR Newswire. August 10, 2015.
- "Allergan Successfully Completes Naurex Acquisition" (Press release). PR Newswire. August 31, 2015.
- "Allergan Successfully Completes AqueSys Acquisition, Adding XEN45 Minimally Invasive Implantable Shunt for Glaucoma" (Press release). PR Newswire. October 19, 2015.
- "Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin" (Press release). PR Newswire. October 1, 2015.
- "Allergan to Acquire earFold™, an Innovative Medical Device for the Correction of Prominent Ears" (Press release). PR Newswire. November 4, 2015.
- "Allergan and Rugen Therapeutics Announce Collaboration to Discover and Develop Ground-Breaking Medicines to Treat Autism Spectrum Disorders and Obsessive-Compulsive Disorders" (Press release). PR Newswire. November 25, 2015.
- "Pfizer seals $160bn Allergan deal to create drugs giant". BBC News. November 23, 2015.
- Rockoff, Jonathan (April 6, 2016). "Pfizer Walks Away From Allergan Deal". The Wall Street Journal.
- "Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders" (Press release). PR Newswire. April 6, 2016.
- "Allergan Acquires Topical Dermatology Company Topokine Therapeutics Adding Non-Invasive Fat Reduction Development Program" (Press release). PR Newswire. April 21, 2016.
- "Allergan plc Completes Divestiture of Global Generics Business to Teva Pharmaceuticals" (Press release). PR Newswire. August 2, 2016.
- "Allergan to Acquire Eye Care Company ForSight VISION5 Adding Peri-Ocular Ring Technology to Company's Leading Portfolio of Innovative Eye Health Products" (Press release). PR Newswire. August 11, 2016.
- "Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company's Innovative Eye Care Pipeline" (Press release). PR Newswire. September 6, 2016.
- Stynes, Tess (September 20, 2016). "Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal". The Wall Street Journal.(subscription required)
- Stynes, Tess (September 21, 2016). "Allergan to Acquire U.K.'s Akarna Therapeutics". The Wall Street Journal.(subscription required)
- "Teva Completes Acquisition of Anda, Inc" (Press release). eva Pharmaceutical Industries. October 3, 2016.
- "Allergan Successfully Completes Vitae Tender Offer" (Press release). PR Newswire. October 25, 2016.
- "Allergan to Acquire GI Disease Subsidiary of Rhythm Holding Company, LLC, Expanding Innovative Gastroenterology Pipeline" (Press release). PR Newswire. October 27, 2016.
- "Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to Alzheimer's Disease" (Press release). PR Newswire. November 22, 2016.
- "Allergan Successfully Completes LifeCell Acquisition" (Press release). PR Newswire. February 1, 2017.
- "Allergan Successfully Completes LifeCell Acquisition" (Press release). PR Newswire. February 1, 2017.
- "Allergan to Acquire Keller Medical, Inc., Adding Keller Funnel® to Company's Leading Plastic Surgery Portfolio" (Press release). PR Newswire. June 7, 2017.
- "Repros Therapeutics Inc.® Announces Acquisition by Allergan plc" (Press release). PR Newswire. December 12, 2017.
- Stempel, Jonathan (January 23, 2018). "New York City sues drug companies over opioid epidemic". Reuters.
- Gurman, Sadie; Mulvihill, Geoff (2 March 2018). "DOJ to Support Lawsuits Against Companies Selling Opioids". Drug Discovery & Development. Advantage Business Media. Associated Press. Retrieved 2 March 2018.